ArticleBMC cancer2026
Germline genetic profiling utilizing multigene panel testing in Jordanian patients with pancreatic cancer: a comprehensive cancer center experience.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths worldwide. Between 5% and 10% of PDACs are attributable to inherited genetic alterations, identification of which may enhance targeted screening and inform treatment decisions. Data on germline variants among Arab patients with PDAC are lacking.
methodsThis prospective study included adult patients with PDAC treated at King Hussein Cancer Center in Amman, Jordan. Patients underwent multigene panel (MGP) testing using either standard or investigational panels. Cascade family testing was offered to relatives of patients with positive results. Germline testing results were classified as benign (negative), pathogenic/likely pathogenic (P/LP) (positive) or variants of uncertain significance (VUS).
resultsA total of 211 patients, all of whom had PDAC as their first cancer diagnosis upon enrollment, were included in the analysis. The median age at diagnosis was 59 years, and 63.0% were males. In total, 22 (10.4%) patients had positive mutations; 14 (6.6%) as pathogenic/likely pathogenic (P/LP) variants, mostly in BRCA2 (n = 8), while 8 others (3.8%) had increased risk allele in APC. Other variants identified included ATM, CFTR, CHEK2, BRCA1, and MSH6. Half (n = 11, 50.0%) of patients with P/LP variants or APC increased risk allele communicated results with their relatives; 18 (69.2%) of 26 relatives tested had positive results.
conclusionsOur study underscores the relevance of PDAC germline genetic testing among the Arab population. Given its clinical implications for screening and management, universal testing should be advocated. Communicating test results with at-risk relatives, despite its importance, remains suboptimal and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.